BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Files An 8-K Entry into a Material Definitive Agreement

Item1.01. Entry into a Material Definitive Agreement.

On March 15, 2017, BioCryst Pharmaceuticals, Inc.(the Company)
entered into a registration rights agreement (the Registration
Rights Agreement) with 667, L.P. and Baker Brothers Life
Sciences, L.P. (collectively, the Baker Entities), both of which
are existing stockholders of the Company. Under the Registration
Rights Agreement, the Company agreed that, if at any time and
from time to time after May 12, 2017, the Baker Entities demand
that the Company register for resale under the Securities Act of
1933, as amended (the Securities Act), the shares of the Companys
common stock held by the Baker Entities, the Company would be
obligated to effect such registration. The Companys registration
obligations under the Registration Rights Agreement cover all
shares of the Companys common stock now held or later acquired by
the Baker Entities, will continue in effect for up to ten years,
and include the Companys obligation to facilitate certain
underwritten public offerings of its common stock by the Baker
Entities in the future. The Registration Rights Agreement is
filed as Exhibit 10.1 hereto and the foregoing description of the
Registration Rights Agreement is qualified in its entirety by
reference to such exhibit.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

About BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Its drug candidates include RAPIVAB, RAPIACTA, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, BCX4430 and Forodesine. Its product RAPIVAB contains peramivir. Peramivir is an intravenous neuraminidase inhibitor approved in various countries for the treatment of patients with influenza, in the United States as RAPIVAB. RAPIVAB is used for the treatment of acute uncomplicated influenza. Its BCX4430 is a broad-spectrum antiviral (BSAV) research program.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Recent Trading Information

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) closed its last trading session up +0.05 at 8.85 with 1,719,390 shares trading hands.